Details der Publikation - A clinical trial for advanced prostatic cancer patients . The study medication will be Leuprolide Mesylate, which will be administered as an injection twice. Both the study doctors and clinical trial participants know which treatment is being administered, there will be only one treatment group.The safety and efficacy of the medicinal product will be tested during the study.

A clinical trial for advanced prostatic cancer patients . The study medication will be Leuprolide Mesylate, which will be administered as an injection twice. Both the study doctors and clinical trial participants know which treatment is being administered, there will be only one treatment group.The safety and efficacy of the medicinal product will be tested during the study. : An Open-Label, Single-Arm Study of the Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate for Injectable Suspension (LMIS 50 mg) in Subjects with Advanced Prostate Carcinoma

Medienart:	Klinische Studie

Erscheinungsjahr:	2023
Erschienen:	2023

Enthalten in:	WHO International Clinical Trials Registry Platform - (2023) vom: 21. Juni Zur Gesamtaufnahme - year:2023

Sprache:	Englisch

Links:	Volltext [kostenfrei]

Themen:	610 Medical Condition: Advanced Prostate Carcinoma MedDRA version: 19.0Level: LLTClassification code 10036921Term: Prostate carcinomaSystem Organ Class: 100000004864;Therapeutic area: Diseases [C] - Cancer [C04] Phase: Phase 3 Recruitment Status: Not yet recruiting Study Type: Interventional

Anmerkungen:	WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 30-06-2014, Last updated: 2023-06-29

ICTRP ID:	EUCTR2013-001790-25-DE FP01C-13-001 2013-001790-25-AT

Förderinstitution / Projekttitel:

PPN (Katalog-ID):	CTG004263790

Internformat


LEADER	01000caa a22002652 4500
001	CTG004263790
003	DE-627
005	20230629100623.0
007	cr uuu---uuuuu
008	210507s2023 xx \|\|\|\|\|o 00\| \|\|eng c
035			\|a (DE-627)CTG004263790
035			\|a (UBBS_Klinische_Studien_WHO)EUCTR2013-001790-25-DE
035			\|a (UBBS_Klinische_Studien_WHO)FP01C-13-001
035			\|a (UBBS_Klinische_Studien_WHO)2013-001790-25-AT
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
245	1	0	\|a A clinical trial for advanced prostatic cancer patients . The study medication will be Leuprolide Mesylate, which will be administered as an injection twice. Both the study doctors and clinical trial participants know which treatment is being administered, there will be only one treatment group.The safety and efficacy of the medicinal product will be tested during the study. \|b An Open-Label, Single-Arm Study of the Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate for Injectable Suspension (LMIS 50 mg) in Subjects with Advanced Prostate Carcinoma
264		1	\|c 2023
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
500			\|a WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 30-06-2014, Last updated: 2023-06-29
650		4	\|a Medical Condition: Advanced Prostate Carcinoma MedDRA version: 19.0Level: LLTClassification code 10036921Term: Prostate carcinomaSystem Organ Class: 100000004864;Therapeutic area: Diseases [C] - Cancer [C04]
650		4	\|a Study Type: Interventional
650		4	\|a Phase: Phase 3
650		4	\|a Recruitment Status: Not yet recruiting
650		4	\|a 610
773	0	8	\|i Enthalten in \|t WHO International Clinical Trials Registry Platform \|g (2023) vom: 21. Juni
773	1	8	\|g year:2023 \|g day:21 \|g month:06
856	4	0	\|u https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2013-001790-25 \|z kostenfrei \|3 Volltext
912			\|a GBV_CTG
951			\|a AR
952			\|j 2023 \|b 21 \|c 06

Zugang & Verfügbarkeit

Zugehörige Publikationen/Bände